The Food and Drug Administration (FDA) calls on the scientific and analytics community to develop innovative applications to explore the relationship between personalized immune repertoires and COVID-19 disease variables and associated factors.
There are two phases, with Phase I focusing on extracting knowledge from molecular sequencing data from TCRs/BCRs and associated clinical variables. Specifically, research tools and workflows developed are anticipated to facilitate our understanding of the relationship between personalized immune repertoires and COVID-19 disease characteristics such as severity and associated factors. Phase I is comprising of two tracks designed to attract participants from the general data science community (DS) and the computational immunology community (CI). Participants are encouraged to participate in either or both track(s).
Deadline: 29th January 2021
For more details: https://precision.fda.gov/challenges/12